Dx Focus: Meridian Illumigene Assays; Biofactory FMR1 Identification Kit | GenomeWeb

Meridian Bioscience said this week that it has received medical device license approval from Health Canada to market its Illumigene Mycoplasma and Pertussis assays.

The Illumigene Mycoplasma test amplifies specific DNA from Mycoplasma pneumonia to detect the bacterium and help patients receive appropriate treatment in a timely manner. Meantime, Illumigene Pertussis amplifies a specific DNA target to detect Bordetella pertussis from nasopharyngeal swabs.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Science this week: certain genes repressed during memory formation, analysis of genomes from single neurons, and more.

NASA plans to test whether DNA sequencing studies can be conducted in microgravity.

Congress passes a continuing resolution to keep the US federal government funded through mid-December.

The Human Genome Project was launched 25 years ago, and at Nature, Francis Collins, James Watson, and Eric Green look back at the lessons learned.